These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24438504)

  • 1. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
    Hagihara A; Ikeda M; Ueno H; Morizane C; Kondo S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Suzuki E; Katayama K; Imanaka K; Tamai C; Inaba Y; Sato Y; Kato M; Okusaka T
    Cancer Sci; 2014 Mar; 105(3):354-8. PubMed ID: 24438504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M; Shimizu S; Sato T; Morimoto M; Kojima Y; Inaba Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T
    Ann Oncol; 2016 Nov; 27(11):2090-2096. PubMed ID: 27573564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
    Lee JE; Bae SH; Choi JY; Yoon SK; You YK; Lee MA
    World J Gastroenterol; 2014 Jan; 20(1):235-41. PubMed ID: 24415877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
    Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
    Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
    Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY; Chao Y
    Int J Cancer; 2013 May; 132(10):2448-58. PubMed ID: 23129123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
    Ikeda M; Okusaka T; Sato Y; Furuse J; Mitsunaga S; Ueno H; Morizane C; Inaba Y; Kobayashi T; Arai Y
    Jpn J Clin Oncol; 2017 Jun; 47(6):512-519. PubMed ID: 28334948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 14. Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
    Terazawa T; Kondo S; Hosoi H; Morizane C; Shimizu S; Mitsunaga S; Ikeda M; Ueno H; Okusaka T
    BMC Cancer; 2014 Apr; 14():301. PubMed ID: 24779747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.